Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics

PURPOSE: Zinc metallochaperones (ZMCs) are a new class of anti-cancer drugs that reactivate zinc deficient mutant p53 by raising and buffering intracellular zinc levels sufficiently to restore zinc binding. In vitro pharmacodynamics of ZMCs indicate that p53 mutant activity is ON by 4–6 hours and is...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Yu, Xin, Kogan, Samuel, Chen, Ying, Tsang, Ashley T., Withers, Tracy, Lin, Hongxia, Gilleran, John, Buckley, Brian, Moore, Dirk, Bertino, Joseph, Chan, Chang, Kimball, S. David, Loh, Stewart N., Carpizo, Darren R.
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6139040/
https://ncbi.nlm.nih.gov/pubmed/29914895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0822
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires